RA Capital Management portfolio · Q2 2026
RA Capital Management, L.P. · CIK 0001346824 ·13F filings on SEC EDGAR
In Q2 2026, RA Capital Management, L.P. reported 84 positions worth $11.5B. Its largest holding was ASND at 23.8% of the portfolio, and the top 10 made up 60%. Its largest new position was ASND ($2.7B), and it sold out of 04351P101.
- NEW 17
- ADD 10
- REDUCE 10
- EXIT 18
Portfolio map
Each box is a position sized by its value. Color shows the change in shares from the previous quarter. The smallest 44 positions are grouped as one box.
Portfolio history
Q4 2025 to Q2 2026, 3 quarters
Weight of the largest holdings
The 7 holdings with the highest weight in any quarter shown, stacked with all others to 100%.
Holding timeline
Shade shows the weight in each quarter. A blank cell means the holding was not reported that quarter.
Holdings
Click a holding to see its price chart with the quarters the investor bought or sold.
| Name | Weight | Avg. cost (est.) | Latest price | Gain/loss | Value |
|---|---|---|---|---|---|
ASND ASCENDIS PHARMA A/S | 23.83% | $266.72 | $227.83 | -14.6% | $2.3B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PBLS PARABILIS MEDICINES INC | 6.88% | $27.37 | $32.29 | +18.0% | $934.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RYTM RHYTHM PHARMACEUTICALS INC | 6.43% | $39.80 | $95.22 | +139.3% | $634.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PCVX VAXCYTE INC | 5.80% | $41.48 | $56.90 | +37.2% | $652.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SION SIONNA THERAPEUTICS INC | 3.79% | $10.46 | $5.26 | -49.7% | $52.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TYRA TYRA BIOSCIENCES INC | 3.39% | $16.19 | $21.87 | +35.1% | $266.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EWTX EDGEWISE THERAPEUTICS INC | 2.96% | $17.65 | $40.60 | +130.0% | $340.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NAMS NEWAMSTERDAM PHARMA CO NV | 2.81% | $13.79 | $24.32 | +76.4% | $232.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
COAG HEMAB THERAPEUTICS HOLDINGS | 2.49% | $36.73 | $30.84 | -16.0% | $240.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SEPN SEPTERNA INC | 2.04% | $22.90 | $39.13 | +70.9% | $273.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BCAX BICARA THERAPEUTICS INC | 1.87% | $25.24 | $18.61 | -26.3% | $135M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MLYS MINERALYS THERAPEUTICS INC | 1.80% | $19.05 | $25.13 | +31.9% | $193.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GHRS GH RESEARCH PLC | 1.78% | $16.65 | $23.48 | +41.0% | $179.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IRON DISC MEDICINE INC | 1.56% | $57.26 | $65.46 | +14.3% | $160.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SGP SPYGLASS PHARMA INC | 1.55% | $25.91 | $26.00 | +0.3% | $208.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ARTV ARTIVA BIOTHERAPEUTICS INC | 1.51% | $12.86 | $7.12 | -44.6% | $127.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JANX JANUX THERAPEUTICS INC | 1.49% | $27.51 | $17.28 | -37.2% | $193.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TSHA TAYSHA GENE THERAPIES INC | 1.39% | $2.70 | $4.87 | +80.2% | $114.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BCRX BIOCRYST PHARMACEUTICALS INC | 1.38% | $7.80 | $8.33 | +6.8% | $131.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
Y95308105 WAVE LIFE SCIENCES LTD | 1.36% | $8.26* | $5.81 | -29.6% | $156.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NUVL NUVALENT INC-A | 1.34% | $94.13 | $123.50 | +31.2% | $153.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABVX ABIVAX SA-ADR | 1.31% | $133.26 | $99.02 | -25.7% | $112.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ORKA ORUKA THERAPEUTICS INC | 1.29% | $95.17 | $83.29 | -12.5% | $129.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CLYM CLIMB BIO INC | 1.28% | $11.66 | $11.47 | -1.6% | $129.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SLDB SOLID BIOSCIENCES INC | 1.04% | $7.48 | $7.23 | -3.3% | $87M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ZLAB ZAI LAB LTD-ADR | 0.95% | $18.81 | $26.34 | +40.0% | $151.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SPRY ARS PHARMACEUTICALS INC | 0.76% | $5.93 | $4.31 | -27.3% | $46.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XNCR XENCOR INC | 0.74% | $12.35 | $24.95 | +102.0% | $131.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JBIO JADE BIOSCIENCES INC | 0.71% | $13.86 | $14.05 | +1.4% | $51.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NTLA INTELLIA THERAPEUTICS INC | 0.67% | $16.92 | $12.06 | -28.7% | $54.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LBRX LB PHARMACEUTICALS INC | 0.62% | $17.05 | $38.38 | +125.0% | $84.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DFTX DEFINIUM THERAPEUTICS INC | 0.61% | $47.04 | $38.06 | -19.1% | $57.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACRS ACLARIS THERAPEUTICS INC | 0.58% | $4.47 | $5.26 | +17.8% | $66.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FDMT 4D MOLECULAR THERAPEUTICS IN | 0.58% | $9.26 | $14.31 | +54.6% | $72.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SANA SANA BIOTECHNOLOGY INC | 0.57% | $3.49 | $2.92 | -16.5% | $54.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
36322Q206 DAMORA THERAPEUTICS INC | 0.54% | $25.90 | $26.01 | +0.4% | $62.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MNPR MONOPAR THERAPEUTICS INC | 0.54% | $32.12 | $79.67 | +148.0% | $53.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABOS ACUMEN PHARMACEUTICALS INC | 0.49% | $8.62 | $2.22 | -74.2% | $46.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GERN GERON CORP | 0.48% | $1.84 | $1.23 | -33.2% | $52.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RZLT REZOLUTE INC | 0.43% | $2.44 | $4.14 | +69.7% | $39.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EVMN EVOMMUNE INC | 0.40% | $17.18 | $8.26 | -51.9% | $28.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VOR VOR BIOPHARMA INC | 0.38% | $26.15 | $19.08 | -27.0% | $45.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IPSC CENTURY THERAPEUTICS INC | 0.38% | $2.26 | $1.71 | -24.3% | $30.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AKTS AKTIS ONCOLOGY INC | 0.37% | $17.89 | $19.47 | +8.8% | $25.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BIOA BIOAGE LABS INC | 0.36% | $17.58 | $7.09 | -59.7% | $11.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CCCC C4 THERAPEUTICS INC | 0.32% | $1.91 | $3.33 | +74.3% | $26.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MIRM MIRUM PHARMACEUTICALS INC | 0.32% | $92.38 | $85.48 | -7.5% | $27.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CAPR CAPRICOR THERAPEUTICS INC | 0.32% | $28.86 | $37.88 | +31.3% | $57.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PEPG PEPGEN INC | 0.31% | $8.06 | $2.42 | -70.0% | $48.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRLD PRELUDE THERAPEUTICS INC | 0.30% | $5.33 | $3.91 | -26.6% | $25.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NKTX NKARTA INC | 0.27% | $21.10 | $2.62 | -87.6% | $28.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
QTTB Q32 BIO INC | 0.26% | $12.74 | $8.27 | -35.1% | $19.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVR ANTERIS TECHNOLOGIES GLOBAL | 0.26% | $5.55 | $7.77 | +40.0% | $23.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EDIT EDITAS MEDICINE INC | 0.25% | $3.24 | $2.57 | -20.7% | $22.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OVID OVID THERAPEUTICS INC | 0.25% | $1.63 | $2.49 | +52.8% | $26.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ASMB ASSEMBLY BIOSCIENCES INC | 0.24% | $25.60 | $23.49 | -8.2% | $24M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALXO ALX ONCOLOGY HOLDINGS INC | 0.23% | $2.00 | $1.39 | -30.7% | $18.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BNTC BENITEC BIOPHARMA INC | 0.22% | $13.47 | $10.00 | -25.8% | $18.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LENZ LENZ THERAPEUTICS INC | 0.21% | $22.33 | $3.84 | -82.8% | $16M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LXEO LEXEO THERAPEUTICS INC | 0.20% | $9.93 | $3.38 | -66.0% | $16.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACRV ACRIVON THERAPEUTICS INC | 0.19% | $6.77 | $2.05 | -69.7% | $25.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALT ALTIMMUNE INC | 0.17% | $3.04 | $2.86 | -5.9% | $18.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KPTI KARYOPHARM THERAPEUTICS INC | 0.16% | $5.57 | $9.77 | +75.4% | $18.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DRUG BRIGHT MINDS BIOSCIENCES INC | 0.16% | $72.97 | $49.82 | -31.7% | $13.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVTX AVALO THERAPEUTICS INC | 0.16% | $12.53 | $15.33 | +22.4% | $15.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OKUR ONKURE THERAPEUTICS INC-A | 0.16% | $4.14 | $2.72 | -34.2% | $10.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FTH FAETH THERAPEUTICS INC | 0.16% | $25.00 | $29.74 | +19.0% | $21.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AURA AURA BIOSCIENCES INC | 0.15% | $7.10 | $6.28 | -11.5% | $15.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SABS SAB BIOTHERAPEUTICS INC | 0.15% | $2.01 | $3.17 | +57.7% | $14M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SPTX SEAPORT THERAPEUTICS INC | 0.13% | $21.72 | $20.17 | -7.1% | $14.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PALI PALISADE BIO INC | 0.13% | $2.35 | $1.35 | -42.6% | $9.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
HLXC HELIX ACQUISITION CORP-CL A | 0.12% | $10.23 | $10.57 | +3.3% | $13.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
WAY WAYSTAR HOLDING CORP | 0.09% | $26.47 | $25.34 | -4.3% | $13.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EQ EQUILLIUM INC | 0.09% | $2.00 | $1.62 | -18.8% | $5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MGNX MACROGENICS INC | 0.07% | $2.89 | $3.86 | +33.6% | $7.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FRNM FREENOME INC | 0.07% | $10.06 | $10.88 | +8.2% | $8.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACET ADICET BIO INC | 0.07% | $8.10 | $7.14 | -11.9% | $6.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NAMSW NEWAMSTERDAM PHARMA CO NV-27 | 0.06% | $0.87 | $12.65 | +1,356.9% | $4.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CRVS CORVUS PHARMACEUTICALS INC | 0.06% | $14.63 | $11.52 | -21.3% | $5.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RANI RANI THERAPEUTICS HOLDINGS-A | 0.06% | $1.35 | $0.79 | -41.4% | $6.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JATT JATT II ACQUISITION CORP | 0.05% | $11.36 | $11.18 | -1.6% | $5.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AMAN AMANAT ACQUISITION CORP CL A | 0.03% | $10.16 | $10.67 | +5.0% | $4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
HOWL WEREWOLF THERAPEUTICS INC | 0.01% | $12.01 | $0.92 | -92.3% | $2.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PTN PALATIN TECHNOLOGIES INC | 0.01% | $15.38 | $8.87 | -42.3% | $551K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
Average cost is an estimate, not the investor's actual purchase price: every quarter the share count rose, the added shares are counted at that quarter-end's 13F price, and sales keep the average. Latest price is the most recent 13F quarter-end price (Sep 30, 2026), and value is shares × latest price. * Held since before Mar 31, 2016, when our collected history starts, so the average starts from that quarter's price.
Changes in shares
Change in shares held vs Mar 31, 2026, for the 20 largest positions that changed. Bars are capped at ±100%; the label shows the actual change.
Sold out this quarter
Held on Mar 31, 2026 and not reported for Q2 2026.
| Stock | Prior weight | Prior shares | Prior value | Change |
|---|---|---|---|---|
| 04351P101 ASCENDIS PHARMA A/S | 24.92% | 10,281,496 | $2.4B | EXIT |
| DNTH DIANTHUS THERAPEUTICS INC | 2.32% | 2,611,733 | $219.2M | EXIT |
| PRAX PRAXIS PRECISION MEDICINES I | 1.28% | 373,787 | $120.4M | EXIT |
| SRPT SAREPTA THERAPEUTICS INC | 0.90% | 3,902,596 | $84.9M | EXIT |
| SYRE SPYRE THERAPEUTICS INC | 0.87% | 1,621,620 | $81.8M | EXIT |
| FULC FULCRUM THERAPEUTICS INC | 0.49% | 6,053,960 | $46.4M | EXIT |
| OLMA OLEMA PHARMACEUTICALS INC | 0.41% | 2,600,000 | $38.8M | EXIT |
| DSGN DESIGN THERAPEUTICS INC | 0.34% | 2,972,973 | $31.6M | EXIT |
| TVTX TRAVERE THERAPEUTICS INC | 0.24% | 746,841 | $22.2M | EXIT |
| GRAL GRAIL INC | 0.23% | 428,266 | $22.1M | EXIT |
| RLMD RELMADA THERAPEUTICS INC | 0.22% | 2,947,369 | $20.5M | EXIT |
| STRO SUTRO BIOPHARMA INC | 0.19% | 715,307 | $17.8M | EXIT |
| CTNM CONTINEUM THERAPEUTICS INC-A | 0.18% | 1,296,012 | $16.9M | EXIT |
| INSP INSPIRE MEDICAL SYSTEMS INC | 0.18% | 325,663 | $16.8M | EXIT |
| HNGE HINGE HEALTH INC-A | 0.15% | 364,613 | $14.1M | EXIT |
| WGS GENEDX HOLDINGS CORP | 0.14% | 209,887 | $13.5M | EXIT |
| RNA ATRIUM THERAPEUTICS INC | 0.12% | 864,102 | $11.6M | EXIT |
| MPLT MAPLIGHT THERAPEUTICS INC | 0.05% | 248,294 | $5M | EXIT |
SEC filings for Q2 2026
- 13F-HR 0001104659-26-097251 · accepted Aug 14, 2026, 20:32 UTC